x
NBC logotype

Conference program

02022-09-06 (pre-conf. day)
12022-09-07
22022-09-08


8.30–12.00

Course: Basic principles of biobanking (only in Swedish)

Kursen riktar sig till verksamhetschefer, forskare, doktorander, läkare, forskningssjuksköterskor, ny biobankspersonal, kvalitetsansvariga, forskningsstödjande personal och andra som kommer i kontakt med biobankning.

Anmälan: Course – Basic principles of biobanking >>
(Observera att den här länken kan användas om du endast har tänkt att anmäla dig till kursen.)

Kursansvarig: Kristina Lind, PhD, Biobank Väst, Göteborg, Sverige

8.30–8.45Välkommen och introduktion
8.45–9.30Introduktion till biobankning och svenska biobankslagen.
Kristina Lind, projektledare Biobank Väst.
9.30–10.00Etikprövning – hur fungerar det och vad bör man tänka på ur ett biobanksperspektiv.
Elin Stenfeldt, projektledare Biobank Väst.
10.00–10.15Fika
10.15–11.15Biobanksansökan – tillgång till prov för forskning.
Elin Stenfeldt, projektledare Biobank Väst.
11.20–12.00Viktiga aspekter vid provtagning och provhantering för biobankning.
Kristina Lind, projektledare Biobank Väst.

12.00–13.00

Workshop A Lunch

13.00–17.00

Workshop A – Quality management- continuous improvement with customer needs (fitness for intended purpose) in mind

Working with quality management is not just documentation; its main pillar is to work in an environment of change and seek continuous improvement. How do we build our organization around quality and how do we find motivation within the organization to achieve higher quality? And who is quality for? In this workshop, we will discuss how biobanks can work with continuous improvement, with customer needs (fitness for intended purpose) in mind, by giving examples from the implementation of ISO20387:2018 Biotechnology –Biobanking- General requirements for biobanking. By the end of the workshop, we aim to have status of where the Nordic countries are today, how we can collaborate, and which direction we would like to head.

Invited speakers

Lennart Gidlöf, Senior Consultant with many years as an expert in international standardization, Sustema, Sweden


Liv Paltiel, Quality Manager at Department for Biobanks at FHI, Folkehelseinstituttet, Norway


Karina Lövstedt, Quality Manager at Biobank Väst, Sweden and chair of Biobank Swedens Network for Implementation of ISO20387, Sweden

Organizers:
Karolin Bergenstråhle: Project Manager, Uppsala Biobank, Sweden (chair) and Malin Åhsblom: Quality Coordinator; Uppsala Biobank, Sweden

15.00–17.00

Workshop B – Automated storage solutions

Investments in automated storage solutions are extensive and costly. Choosing the optimal solution in each case is crucial both now, and in the future. One of the key decisions is to select the temperature for the storage: What scientific evidence should contribute to the selection of a specific storage temperature? Why do the vendors offer different temperature solutions? What are the consequences of choosing a specific temperature? In this workshop we will try to highlight such questions, by inviting some of the providers of automated stores for a discussion around it. We will also touch challenges with established stores in the Nordic countries, like service and maintenance during the pandemics.

Invited speakers

Lutz Doms, CEO, Askion GmbH

Donat Elsener, Director Sales & Marketing, Hamilton Storage GmbH

Organizers:
Biobank Norway: Kristian Hveem, Professor, Head of Hunt Biobank, HUNT Research Centre – Norwegian University of Science and Technology, Anne Jorunn Vikdal, Project coordinator/Biomedical Laboratory Scientist, Hunt Research Centre, Biobank, Quality manager, Biobank Norway, Norway Vegard Marschhäuser, Project coordinator, HUNT Research Centre – Norwegian University of Science and Technology

15.00–17.00

Workshop C – Education in biobanking

Education is important, in biobanking and everywhere else. In biobanking, much education and training take place in front of an instrument or freezer, and is taught by the nearest co-worker or local super user. There are, however, also a number of courses for biobankers dealing with topics such as sample quality, ethical and legal perspectives, laboratory management and research perspectives. In this workshop we will hear from organisers of Nordic biobank courses and expand to European options.

Invited speakers

Lasse Boding, Danish National Biobank, “Take home from the annual PhD course: Biobanking in the era of personalised medicine”. 


Tina Bossow, Global Expert within Human Biosample Governance, Novo Nordisk, “Experiences from Certificate – Principles in Biobanking, Luxembourg and Master of Science in Biobanking, University of Graz.”

Organizer:
Lasse Boding, PhD, Head of Coordinating Centre, Danish National Biobank. Statens Serum Institut, Denmark

17.30–19.00

Welcome Reception by the city of Gothenburg in collaboration with Region Västra Götaland and includes a buffet and drinks. The reception is open for all registered participants.

Pre-registration is mandatory.

02022-09-06 (pre-conf. day)
12022-09-07
22022-09-08


8.00–9.00

Registration

9.00–9.10

Welcome

9.10–9.50

Keynote speaker

Professor Aarno Palotie, FinnGen
Very large-scale biobank projects, experiences from FinnGen

Professor Aarno Palotie, M.D., Ph.D. is the research director of the Human Genomics program at FIMM-HiLife. He is also a faculty member at the Center for Human Genome Research at the Massachusetts General Hospital in Boston and associate member of the Broad Institute of MIT and Harvard. He has a long track record in human disease genetics. He has hold professorships and group leader positions at the University of Helsinki, UCLA and Wellcome Trust Sanger Institute. He has also been the director of the Finnish Genome Center and Laboratory of Molecular Genetics in the Helsinki University Hospital. He is the Scientific Director of the large FinnGen project that combines the genome and national health record data from 500 000 Finnish participants.

Aarno Palotie

9.50–10.30

Keynote speaker

Professor Hilma Holm, deCODE genetics

Hilma Holm, MD, is the head of the Cardiovascular Research Department at deCODE genetics in Reykjavik, Iceland. She is an expert in echocardiology, cardiovascular genetics and population genetics research. Dr. Holm is actively involved in a wide range of genetic research, including on lipids and atherosclerosis, cardiac conduction and arrhythmias, congenital heart disesae, valve disease and heart failure. Dr. Holm also directs the deCODE Health Study, a prospective cohort study in Iceland with extensive phenotypic and genotypic information.

10.30–11.00

Coffee break – Exhibition and Posters

11.00–12.30

Symposium 1

Combining registries with biobank samples

Stored human biological material suitable for modern molecular analysis in combination with clinical and demographic registries are the most critical resources for research-based translation of advances in molecular biology and advanced technologies into improved human health.  The in-depth characterization of human diversity as dictated by variation in the sequences of genomes is now possible on a population-scale. Coupled with longitudinal information about disease risk factors, etiological processes and outcomes, an unparalleled opportunity currently exists to optimize prevention, diagnosis, and treatment of many acute and chronic diseases.

Invited speakers

Henrik Ullum, CEO, Statens Serum Institut, Denmark

Understanding health and disease by leveraging the potential of large national biobanks and health registries


Åke Lernmark, Senior Professor, Lund University, Sweden

The TEDDY study – understanding diabetes in the young by combining big data and biobanking.


2 Oral Abstract presenters
(to be announced)

Chair: Lasse Boding, PhD, Head of Coordinating Centre, Danish National Biobank. Statens Serum Institut, Denmark. 

12.30–14.00

General Lunch in Exhibit Hall – Exhibition & Posters

14.00–15.30

Symposium 2a

Sample quality

During the sample quality session, the topics will include sampling techniques and the effect of sampling on sample quality, the impact of sample quality on false findings in research, and how to classify and control for sample quality which is “fit for purpose”. 

Invited speakers

Laura Goobar Larsson, PhD, Line Manager, Biobank och Studier, Karolinska University Laboratory, Sweden


Anne Jorunn Vikdal, Project coordinator/Biomedical Laboratory Scientist, HUNT Biobank, Quality manager, Biobank Norway, Norway


Panel discussion, topic:
Minimizing Sampling Bias – how to make samples usable in the long perspective and to avoid false positive and false negative findings.

Panel participants:
Anne Jorunn Vikdal, Project coordinator/Biomedical Laboratory Scientist, HUNT Biobank, Quality manager for Biobank  Norway
Laura Goobar Larsson, PhD, Line Manager, Biobank och Studier, Karolinska University Laboratory, Sweden


2 Oral Abstract presenters
(to be announced)

Chair: Åsa Torinsson Naluai, Associate Professor at Sahlgrenska Academy and Biobank Väst at Sahlgrenska University Hospital, Sweden

14.00–15.30

Symposium 2b

Biobank research brings a number of ethical and societal challenges such as finding appropriate avenues to inform participants about data and sample uses, involving participants in the research processes, and ensuring that participant trust and stakeholder engagement is maintained. In this session, particular focus will be put on some key ethical considerations in biobanking including and approaches for the ethically and legally robust sharing of data between Nordic countries. 

Invited speakers

Ann M. Gronowski, PhD, Professor of Pathology & Immunology, and Obstetrics & Gynecology at Washington University School of Medicine in St. Louis, USA

Ethical issues in laboratory medicine


Heidi Beate Bentzen, PhD, Researcher, University of Oslo, Norway

Data sharing between countries


2 Oral Abstract presenters
(to be announced)

Chair: Isabelle Budin Ljøsne, PhD, Norwegian Institute of Public Health/ Biobank Norway – CS2 ELSI Norway 

15.30–16.00

Coffee break – Exhibition and Posters

16.00–17.30

Symposium 3a

Next generation biobanking

This session will address the topic from several angles.

The current pandemic has shown that established biobanks may play a new and crucial role as an invaluable clinical platform for contingency studies of a new and life-threatening disease where valid prospective, population-based research is pivotal. We see an outline of a next generation biobanking contributing more directly and immediate to clinical translation of research.

Biobanks struggle with incomplete technical solutions and huge costs for automated storage at ultralow temperatures. Will new technologies markedly change the handling of biobank samples? Is Room Temperature Samples Storage (RTSS) the future solutions? 

Invited speakers

Bart Wilkowski, PhD, Head of IT, Denmark National Biobank, Statens Serum Institut, Denmark 


Thomas Illig, Professor, MD, PhD, Scientific Head of Hannover Unified Biobank, Head of Research of the Department of Human Genetics, Medizinische Hochschule Hannover, Germany


2 Oral Abstract presenters
(to be announced)

Chair: Kristian Hveem, Professor, Norwegian University of Science and Technology, Biobank Norway, Norway

16.00–17.30

Symposium 3b

Biobank sustainability

Building up a sustainable biobank infrastructure includes challenges and opportunities. In this session we will discuss different strategies biobanks can adopt towards sustainable biobanking. Examples will be given of public-private partnerships, the creation of new resources to increase the value of the biobank and providing new types of research services. In addition, ways to advertise and present the biobank resources to the large research community will be explored.

Invited speakers

Tba


Kristian Hveem, Professor, Head of Hunt Biobank, Biobank Norway – Norwegian University of Science and Technology, Norway


2 Oral Abstract presenters
(to be announced)

Chair: Tba

17.30–17.45

Wrap up the day

19.00–

Conference dinner

Pre-registration is mandatory.

Venue tba.

02022-09-06 (pre-conf. day)
12022-09-07
22022-09-08


8.50–9.00

Welcome

9.00–10.30

Symposium 4a

Nordic biobanks roles in pandemic

In this session different ways to utilize biobanks in Covid19 research will be described, such as the collection of new samples to study long covid, linking genomic biobank data with hospital and register data to provide insight into disease development, and how the biobank infrastructure was harnessed to develop mass testing of covid19 in the population. These provide good examples for how biobank infrastructures can support the study of emerging pandemics.

Invited speakers

Markus Perola, Research Professor, THL Biobank, Finland

Utilizing Finnish biobanks in Covid19 research 


Karina Meden Sørensen, Section Leader, Laboratory Manager, Statens Seruminstitut, SSI, Denmark


2 Oral Abstract presenters, to be announced.

Chair: tba

9.00–10.30

Symposium 4b

Good examples of biobank research

As Biobanks can give researchers access to samples from a large number of people they have become a very efficient and important resource in medical research. Thus, they are supporting cutting edge research in e.g. genomics and personalized medicine. The session will provide a broad perspective as well as specific examples on excellent research based on biobanks.

Invited speakers

Mark Divers, PhD, Director Karolinska Institutet Biobank, Sweden

Biobanks make a difference: why Time magazine and Forbes got it right


Jonas Ghouse, MD, PhD, Laboratory of Molecular Cardiology, Copenhagen University Hospital, Denmark

Use of genetic profiling of a large biobank combined with prescription patterns to discover genetic loci associated with adverse drug reactions


2 Oral Abstract presenters, to be announced.

Chair: Erik Sørensen, MSc, PhD, Operational Director Copenhagen Hospital Biobank Unit

10.30–11.00

Coffee break – Exhibition & Posters

11.00–12.30

Symposium 5a

Infrastructure

The infrastructure of Biobank Sweden aims to give Sweden the best prerequisites for healthcare and research within the biobank area, both national and international. 

AstraZeneca’s vision is a global biobank infrastructure with visibility, in full compliance with ethical and legal standards and rapid access to samples.

In this session we will also address the EU clinical trial regulation, which came into force in January 2022, and discuss some of the obvious possibilities and hidden obstacles in getting the much-needed infrastructure in place.

Invited speakers

Sonja Eaker Fält, PhD, Head of Biobank Sweden

Biobank Sweden, a national infrastructure with regional availability


Karin Gedda, PhD, Associate Director from AstraZeneca, Sweden

Biobanking from a global perspective


2 Oral Abstract presenters, to be announced.

Chair: Camilla Hildesjö, Med Lic, Custodian Biobank Östergötland, Regionalt Biobankscentrum, Linköping, Sweden

11.00–12.30

Symposium 5b

Patient engagement and return of genomic data

Health care is moving towards patient-centered and precision medicine where biobanking-based research will play an important role. In this symposium we will discuss biobanking from the patients perspective as perceived by a patient advocate and a genetic counsellor. Both have extensive experience in representing patient interest in an area of different stakeholders. We will address weaknesses in the legal framework and ethical dilemmas hindering optimal biobanking.

Traditionally, the role of patients has been as research study participants. But with the patient-centred healthcare, its more accepted to have them as collaborators in the study design, development, and governance of biobanks as well as for future strategies. Dynamic consent for empowerment of patients/participants will also be addressed.

Invited speakers

Vigdis Stefansdottir, MD, University of Iceland, Iceland


Margareta Haag, Chair of the network against cancer, Sweden


2 Oral Abstract presenters, to be announced.

Chair: Jon Johannes Jonsson, professor, University of Iceland, Iceland

12.30–13.30

General Lunch in Exhibit Hall – Exhibition & Posters

13.30–15.00

Symposium 6a

Digitalization

What can digitalization offer biobanks and biobank research? New ways to visualize vast amounts of data, explore different scenarios and obtain novel research ideas will be shown, including health register data and genomic data. In addition, developing digital services for biobank sample donors, built inside the hospital settings will be described. These include consent management and recontact of donors.

Invited speakers

Aki Lehto (ICT-Architect), Tampere University Hospital, Finland

OmaTays – enabling digital consent interaction for Tampere Biobank


Toni Mikkola, Data Scientist, Tampere University Hospital, Finland

Short introduction to unstructured patient records, – From regular expressions to text classification


2 Oral Abstract presenters, to be announced.

Chair: Kimmo Savinainen, Deputy Head of Finnish Clinical Biobank Tampere, Tampere University Hospital, Finland

13.30–15.00

Symposium 6b

Innovative technologies

New developments from all directions are transforming biobanking and making it possible to do so much more with samples and data that represent complex biology. This symposium will look at some examples of technology leaps that either build on biobanks or transform what they can do.

Invited speakers

Mattias Rantalainen, Lecturer Senior, Karolinska Institutet, Sweden


Päivi Östling, Researcher, Karolinska Institutet, Sweden

Material flows needed for multi-onic and functional precision medicine.


2 Oral Abstract presenters, to be announced.

Chair: Mark Divers, BSc PhD, Director, Karolinska Institutet Biobank, Sweden

15.00–15.20

Coffee break – Exhibition & Posters

15.20–16.05

Panel discussion – Collaboration between Nordic Biobanks

Moderator:

Frida Lundmark, The Swedish Association of the Pharmaceutical Industry, LIF

Panel:

Sweden: Sonja Eaker Fält, Biobank Sweden
Norway: Kristian Hveem, NTNU, Biobank Norway
Denmark: Lasse Boding, Danish National Biobank
Finland: Sirpa Soini, THL Biobank, Finland
Iceland: Jon Jonsson, University of Iceland, Iceland

16.05–16.15

Wrap up the day